In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Scilex Holding Company (SCLX – Research Report), with a price target of $4.00. Mayank Mamtani’s Buy ...

Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Cytokinetics (CYTK – Research Report) and keeping the price target at $92.00. Mayank Mamtani has given his Buy rating due ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial downgraded MacroGenics (MGNX – Research Report) to a Hold, with a price target of $5.00. Mayank Mamtani has given his Hold ...

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $22.00. Mayank Mamtani provided ...

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Harrow Health (HROW – Research Report), with a price target of $73.00. Mayank Mamtani has given his ...

B. Riley Securities Managing Director & Group Head of Healthcare Research Mayank Mamtani joins Market Domination to break down the deal. The co-exclusive licensing agreement between the two ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Scilex Holding Company (SCLX – Research Report) today and set a price target of $4.00. Mayank Mamtani has given his Buy rating ...

B.Riley Financial analyst Mayank Mamtani has reiterated their bullish stance on DNLI stock, giving a Buy rating today. Mayank Mamtani has given his Buy rating due to a combination of factors ...

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on Harrow Health (HROW – Research Report), boosting the price target to $73.00. Mayank Mamtani has given his Buy rating due to ...

B. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a price target of $1.50, up from $1.The company’s topline results from the Phase 2 SHIMMER study ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price target of $4.00. The company’s shares closed ...